Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
暂无分享,去创建一个
Shi-Yong Neo | K. Lam | Shengli Xu | Joni Chong | Jing Wu
[1] H. Ljunggren,et al. Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia , 2022, Journal for immunotherapy of cancer.
[2] Y. Liu,et al. Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy , 2022, Science Translational Medicine.
[3] Yanqi Yu,et al. Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity , 2022, Cancers.
[4] Hiu Ting Chan,et al. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy , 2022, Journal of translational medicine.
[5] F. Marofi,et al. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction , 2022, Cancer cell international.
[6] Baorui Liu,et al. Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer , 2022, Human vaccines & immunotherapeutics.
[7] C. Pan,et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy , 2022, Journal of experimental & clinical cancer research : CR.
[8] Z. Berneman,et al. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells , 2022, Journal of Translational Medicine.
[9] J. Thaxton,et al. B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity , 2021, Journal for ImmunoTherapy of Cancer.
[10] Dariusz M Plewczynski,et al. PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress , 2021, Cancer Immunology Research.
[11] Sagar M. Utturkar,et al. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells , 2021, Proceedings of the National Academy of Sciences.
[12] Zhongen Wu,et al. Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy , 2021, Frontiers in Pharmacology.
[13] Chenya Wang,et al. Coupling programmed cell death 1-positive tumor-infiltrating T cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy. , 2021, Cytotherapy.
[14] G. Lucchini,et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial , 2021, Nature Medicine.
[15] Chaoliang He,et al. Localized Chemotherapy Based on Injectable Hydrogel Boosts the Antitumor Activity of Adoptively Transferred T Lymphocytes In Vivo , 2021, Advanced healthcare materials.
[16] M. Ernstoff,et al. Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors , 2021, Journal for ImmunoTherapy of Cancer.
[17] W. Cho,et al. A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers , 2021, Frontiers in Oncology.
[18] Joseph C. Sun,et al. Natural Killer Cells: From Innate to Adaptive Features. , 2021, Annual review of immunology.
[19] A. Logan,et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. , 2021, Blood.
[20] Ziyan Zhang,et al. Coating with flexible DNA network enhanced T-cell activation and tumor killing for adoptive cell therapy , 2021, Acta pharmaceutica Sinica. B.
[21] Rosalie M Sterner,et al. CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.
[22] Howard Y. Chang,et al. Transient “rest” restores functionality in exhausted CAR-T cells via epigenetic remodeling , 2021, Science.
[23] Xiaomei Wang,et al. Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] G. Church,et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions , 2020, Journal of Hematology & Oncology.
[25] Zhiyuan Niu,et al. Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunity , 2020, The Journal of pathology.
[26] P. Hegde,et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. , 2020, Cancer discovery.
[27] W. Wels,et al. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma , 2020, Frontiers in Immunology.
[28] Tali Raveh-Sadka,et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis , 2020, Nature Medicine.
[29] S. Galimberti,et al. Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. , 2020, The Journal of clinical investigation.
[30] K. Yasumoto,et al. Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix , 2020, AntiCancer Research.
[31] Jason S. Mitchell,et al. Adoptive T Cell Therapy with IL-12–Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity , 2020, The Journal of Immunology.
[32] F. Gao,et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. , 2020, Blood.
[33] J. Schachter,et al. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia , 2020, Frontiers in Immunology.
[34] M. Lotze,et al. Oncolytic Virus Promotes Tumor-Reactive Infiltrating Lymphocytes for Adoptive Cell Therapy , 2020, Cancer Gene Therapy.
[35] D. Kaufman,et al. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. , 2020, Cell stem cell.
[36] Yao Huang,et al. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro , 2020, Cancer management and research.
[37] Martha E. Zeeman,et al. Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.
[38] T. Barington,et al. Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review , 2020, Frontiers in Immunology.
[39] P. Thall,et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.
[40] S. Asgharzadeh,et al. Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages , 2020 .
[41] E. Reinherz,et al. Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display , 2019, Front. Immunol..
[42] Huilan Wang,et al. Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor , 2019, Front. Oncol..
[43] Daofeng Liu,et al. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma , 2019, Clinical Cancer Research.
[44] C. Klebanoff,et al. T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance , 2019, Immunological reviews.
[45] B. Solomon,et al. Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression , 2019, Science Translational Medicine.
[46] A. Zhu,et al. Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells , 2019, Science Advances.
[47] Xiaobo Xi,et al. Magnetic Nanoclusters Armed with Responsive PD-1 Antibody Synergistically Improved Adoptive T-Cell Therapy for Solid Tumors. , 2019, ACS nano.
[48] Bainan Liu,et al. Target selection of CAR T cell therapy in accordance with the TME for solid tumors. , 2019, American journal of cancer research.
[49] O. Lantz,et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.
[50] D. Kaufman,et al. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.
[51] H. Lokhorst,et al. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design , 2018, PloS one.
[52] A. Eliseev,et al. Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[53] Theresa Kaeuferle,et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia , 2018, Cancer Immunology, Immunotherapy.
[54] Junnian Zheng,et al. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE , 2018, Cancer biology & therapy.
[55] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[56] K. Gustafsson,et al. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[57] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[58] A. Ashworth,et al. Reprogramming human T cell function and specificity with non-viral genome targeting , 2017, bioRxiv.
[59] A. Lundqvist,et al. Correction to: Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma , 2017, Journal of Immunotherapy for Cancer.
[60] Ping Chen,et al. Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy , 2017, Journal of Translational Medicine.
[61] J. Jansen,et al. Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients , 2017, Clinical Cancer Research.
[62] R. Brentjens,et al. Adoptive T-Cell Therapy for Solid Tumors. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[63] F. Claas,et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia , 2016, Science Translational Medicine.
[64] M. Baker,et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. , 2016, The Journal of clinical investigation.
[65] G. Roselli,et al. Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model , 2016, Oncotarget.
[66] L. Naldini,et al. IFNα gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment , 2016, EMBO molecular medicine.
[67] S. Grupp,et al. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies , 2016, Science Translational Medicine.
[68] M. Sadelain,et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.
[69] Alexandria P. Cogdill,et al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. , 2015, Cancer research.
[70] I. Pastan,et al. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1&agr;-secreting Glioblastoma , 2015, Journal of immunotherapy.
[71] F. Locatelli,et al. gd T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR- ab 1 /CD19 1 lymphocytes , 2016 .
[72] K. Curran,et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[73] Sadik H. Kassim,et al. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.
[74] M. Brown,et al. Mini Review Article , 2022 .
[75] Hao Liu,et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. , 2014, Cancer research.
[76] E. Andersson,et al. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma , 2014, Cancer Immunology, Immunotherapy.
[77] M. Shokrgozar,et al. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy. , 2014, Biochimica et biophysica acta.
[78] E. Seifried,et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. , 2013, Cytotherapy.
[79] B. Zhivotovsky,et al. Doxorubicin sensitizes human tumor cells to NK cell‐ and T‐cell‐mediated killing by augmented TRAIL receptor signaling , 2013, International journal of cancer.
[80] Jennifer G. Abelin,et al. MHC Class I–Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia , 2013, Science Translational Medicine.
[81] H. Okamura,et al. Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells , 2013, Cancer Immunology, Immunotherapy.
[82] E. Alici,et al. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. , 2012, Human gene therapy.
[83] M. Sadelain,et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.
[84] S. Eccles,et al. Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling , 2012, Journal of Clinical Immunology.
[85] Lei Zhang,et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.
[86] L. Moretta,et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. , 2011, Blood.
[87] E. Oldfield,et al. Indirect Stimulation of Human Vγ2Vδ2 T Cells through Alterations in Isoprenoid Metabolism , 2011, The Journal of Immunology.
[88] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] A. Amir,et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity , 2010, Proceedings of the National Academy of Sciences.
[90] T. Schumacher,et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy , 2010, Nature Medicine.
[91] A. Seltsam,et al. Permanent silencing of NKG2A expression for cell-based therapeutics , 2009, Journal of Molecular Medicine.
[92] R. Negrin,et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. , 2008, Blood.
[93] M. Caligiuri,et al. Human natural killer cells. , 2008, Blood.
[94] K. Nakagawa,et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. , 2008, Cytotherapy.
[95] Hong Wang,et al. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens , 2007, Immunological reviews.
[96] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[97] Y. Togashi,et al. Critical role of the Th1/Tc1 circuit for the generation of tumor‐specific CTL during tumor eradication in vivo by Th1‐cell therapy , 2003, Cancer science.
[98] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[99] T. Schumacher,et al. Immunotherapy through TCR gene transfer , 2001, Nature Immunology.
[100] Z. Eshhar,et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[101] L. Hood,et al. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: Implications for T cell receptor complex formation and activation , 1990, Cell.
[102] S. Rosenberg,et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.
[103] A. Chang,et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.